Sugi Predict

Sugi Predict / Targets / PTPRZ1

PTPRZ1

Receptor-type tyrosine-protein phosphatase zeta · P23471 · PTPRZ1 on Sugi Atlas →

2,171 patent compounds predicted against PTPRZ1, 1,013 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3306295 SCHEMBL3306295 0.70 4/20
SCHEMBL11081323 SCHEMBL11081323 0.69 4/20
SCHEMBL6002206 SCHEMBL6002206 0.69 4/20
SCHEMBL10873420 SCHEMBL10873420 0.69 4/20
SCHEMBL6001747 SCHEMBL6001747 0.65 4/20
SCHEMBL3306293 SCHEMBL3306293 0.65 4/20
SCHEMBL963353 SCHEMBL963353 0.63 4/20
SCHEMBL5563665 SCHEMBL5563665 0.62 4/20
SCHEMBL9108524 SCHEMBL9108524 0.61 4/20
SCHEMBL95318 SCHEMBL95318 0.61 4/20
SCHEMBL95319 SCHEMBL95319 0.61 4/20
SCHEMBL257111 SCHEMBL257111 0.61 4/20
SCHEMBL697792 SCHEMBL697792 0.61 4/20
SCHEMBL712441 SCHEMBL712441 0.61 4/20
SCHEMBL1146178 SCHEMBL1146178 0.61 4/20
SCHEMBL5404852 SCHEMBL5404852 0.61 4/20
SCHEMBL7053864 SCHEMBL7053864 0.61 4/20
SCHEMBL10802654 SCHEMBL10802654 0.61 4/20
SCHEMBL9676417 SCHEMBL9676417 0.59 4/20
Ethane Ethane (SCHEMBL11401460) 0.59 4/20

Clinical trials — most relevant to PTPRZ1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation PHASE2COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation nanRECRUITING
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPRZ1 binder may also engage these)

ProteinNameSimilarity
Q62656 — 1.000 Q62656 →
B9EKR1 — 1.000 B9EKR1 →
Q80XH2 — 0.992 Q80XH2 →
Q8VD58 — 0.991 Q8VD58 →
Q62059 — 0.989 Q62059 →
B7ZCC9 — 0.989 B7ZCC9 →
Q9ET62 — 0.989 Q9ET62 →
Q9D5A0 — 0.989 Q9D5A0 →
A6NHS7 — 0.989 A6NHS7 →
Q1XI86 — 0.989 Q1XI86 →
Q8IZF6 — 0.988 Q8IZF6 →
Q5RII3 — 0.988 Q5RII3 →
P70628 — 0.987 P70628 →
Q9D2S4 — 0.987 Q9D2S4 →
Q2TA21 — 0.987 Q2TA21 →
P81282 — 0.985 P81282 →
Q30KK0 — 0.985 Q30KK0 →
Q28858 — 0.985 Q28858 →
Q9ERB4 — 0.985 Q9ERB4 →
Q9BZV3 — 0.985 Q9BZV3 →
P16744 — 0.984 P16744 →
A0JPP4 — 0.984 A0JPP4 →
P34910 — 0.984 P34910 →
Q8JIR8 — 0.983 Q8JIR8 →
Q69558 — 0.983 Q69558 →
Q3ZRW6 — 0.983 Q3ZRW6 →
Q77NN4 — 0.983 Q77NN4 →
Q12282 — 0.983 Q12282 →
Q8R1W8 — 0.983 Q8R1W8 →
Q6WRI0 — 0.983 Q6WRI0 →